Acquire Therapeutics information SEC registration assertion for its preliminary public providing


BETHESDA, MD, March 10, 2021 (GLOBE NEWSWIRE) – Acquire Therapeutics, Inc. (“Acquire”) right this moment introduced that it has launched the roadshow for its IPO of its widespread inventory. Acquire is providing 3,636,364 shares of its widespread inventory. The preliminary public providing value is predicted to be between $ 10.00 and $ 12.00 per share, earlier than subscription rebates and commissions. As well as, Acquire expects to grant the Underwriters a 30-day choice to buy as much as 545,454 extra Widespread Shares on the preliminary public providing value, much less subscription rebates and commissions. Acquire has utilized to record its widespread shares on the Nasdaq World Choose Market underneath the image “GANX”.

BTIG, LLC and Oppenheimer & Co. Inc. are performing as bookkeepers for the proposed providing. Nationwide Securities Company can also be performing as co-manager of the proposed providing.

The proposed supply will solely be made by the use of a prospectus. Copies of the preliminary prospectus referring to the proposed providing could also be obtained, when out there, freed from cost by visiting EDGAR on the SEC’s web site at Alternatively, copies of the preliminary prospectus, when out there, could also be obtained freed from cost from the workplaces of BTIG, LLC, consideration: Fairness Capital Markets, 65 East fifty fifth Avenue, New York, New York 10022, by phone at 212-593-7555, or by e mail at [email protected]; Oppenheimer & Co. Inc., by Oppenheimer & Co. Inc., Attn .: Syndicate Prospectus Division, 85 Broad Avenue, twenty sixth Flooring, New York, New York 10004, by telephone at 212-667-8055, or by e mail to EquityProspectus @; or Nationwide Securities Company, by Nationwide Securities Company, Attn .: Adrian Adderley, 200 Vesey Avenue, twenty fifth Flooring, New York, New York 10281, by telephone at (561) 981-1074, or by e mail at prospectusrequest @ nationalsecurities .com. The supply is topic to market and different situations and there will be no assurance if or when the supply will be made.

A registration assertion referring to the proposed sale of those securities has been filed with the SEC however has not but come into impact. These securities can’t be offered, nor the presents to purchase accepted, earlier than the second when the registration declaration comes into power. This launch doesn’t represent a suggestion to promote or the solicitation of a suggestion to purchase, and there will probably be no sale of such securities in any state or jurisdiction by which such a suggestion, solicitation or sale can be unlawful earlier than the ‘registration or qualification underneath the securities legal guidelines of these states or jurisdictions.

About Acquire Therapeutics, Inc.

Acquire Therapeutics is redefining drug discovery with its See-Tx ™ goal identification platform. By figuring out and optimizing allosteric binding websites that had by no means been focused earlier than, Acquire opens up new therapy choices for difficult-to-treat problems characterised by protein misfolding. In July 2020, Acquire Therapeutics, Inc. entered right into a share trade with Acquire Therapeutics, SA, a Swiss firm, whereby GT Acquire Therapeutics SA turned a wholly-owned subsidiary of Acquire Therapeutics, Inc.

Contact with Acquire Therapeutics buyers:
Daniel Ferry
LifeSci Advisors
+1 617-430-7576
[email protected]

Acquire Therapeutics media contact:
Cait Williamson, Ph.D.
LifeSci Communications
+1 646-751-4366
[email protected]

Supply hyperlink

Leave A Reply

Your email address will not be published.